PLANTATION, Fla., Feb. 1 /PRNewswire-FirstCall/ -- Viragen, Inc. today announced that the Company is scheduled to make a presentation at the BIO CEO & Investor Conference to be held in New York City during February 12-14, 2007.
Event Details: Meeting: Biotechnology Industry Organization (BIO) CEO & Investor Conference Presenter: Charles A. Rice, President & CEO, Viragen, Inc. Date / Time: Tuesday, February 13th at 3:45 p.m. Place: Waldorf-Astoria Hotel, New York City
The Company will conduct additional one-on-one meetings with institutional investors, fund managers and investment bankers. To request and schedule a meeting, please contact Douglas Calder, Director of Communications, at (954) 233-8746 or at dcalder@viragen.com.
In other news, Viragen reported voting results from its 2006 Annual Meeting of Stockholders held on January 25, 2007 in Plantation, Florida.
Stockholders approved all proxy voting items including: - Reelection of Carl N. Singer and C. Richard Stafford as Class C members of the Company’s Board of Directors - Viragen’s 2006 Equity Compensation Plan - Amendment to Viragen’s Certificate of Incorporation to increase the number of shares of common stock it is authorized to issue, from 250 million to 500 million - Appointment of Ernst & Young LLP, as Viragen’s independent registered public accounting firm for the fiscal year ending June 30, 2007 About Viragen, Inc.:
With international operations in the U.S., Scotland and Sweden, we are a bio-pharmaceutical company engaged in the research, development, manufacture and commercialization of therapeutic proteins for the treatment of cancers and viral diseases. Our product and product candidate portfolio includes: Multiferon(R) (multi-subtype, human alpha interferon) which is uniquely positioned in valuable niche indications, such as high-risk malignant melanoma, other niche cancer indications and selected infectious diseases; VG101, a humanized monoclonal antibody that binds selectively to an antigen over-expressed on Stage IV malignant melanoma tumors; and VG102, a highly novel humanized monoclonal antibody that binds selectively to an antigen that is over-expressed on nearly all solid tumors. We are also pioneering the development of the OVA(TM) System (Avian Transgenics), with the renowned Roslin Institute, the creators of “Dolly the Sheep”, as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies, by expressing these products in the egg whites of transgenic hens.
For more information, please visit: http://www.Viragen.com Viragen, Inc. Corporate Contact: Douglas Calder, Director of Communications Phone: (954) 233-8746; Fax: (954) 233-1414 E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the success of third- party marketing efforts; our ability to retain third-party distributors; our ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Photo: http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-bAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comViragen, Inc.
CONTACT: Douglas Calder, Director of Communications of Viragen, Inc.,+1-954-233-8746, or fax, +1-954-233-1414, or dcalder@viragen.com
Web site: http://www.viragen.com/
